Kadurugamuwa J L, Beveridge T J
Canadian Bacterial Diseases Network, Department of Microbiology, College of Biological Science, University of Guelph, Ontario, Canada.
Antimicrob Agents Chemother. 1998 Jun;42(6):1476-83. doi: 10.1128/AAC.42.6.1476.
We developed a model to test whether non-membrane-permeative therapeutic agents such as gentamicin could be delivered into mammalian cells by means of bacterial membrane vesicles. Many gram-negative bacteria bleb off membrane vesicles (MVs) during normal growth, and the quantity of these vesicles can be increased by brief exposure to gentamicin (J. L. Kadurugamuwa and T. J. Beveridge, J. Bacteriol. 177:3998-4008, 1995), which can be entrapped within the MVs. Gentamicin-induced MVs (g-MVs) were isolated from Shigella flexneri and contained 85 +/- 2 ng of gentamicin per microgram of MV protein. Immunogold electron microscopic labeling of thin sections with antibodies specific to S. flexneri lipopolysaccharide (LPS) demonstrated the adherence and subsequent engulfment of MVs by the human Henle 407 intestinal epithelial cell line. Further incubation of g-MVs with S. flexneri-infected Henle cells revealed that the g-MVs penetrated throughout the infected cells and reduced the intracellular pathogen by approximately 1.5 log10 CFU in the first hour of incubation. Antibiotic was detected in the cytoplasms of host cells, indicating the intracellular placement of the drug following the penetration of g-MVs. Soluble antibiotic, added as a fluid to the tissue culture growth medium, had no effect on intracellular bacterial growth, confirming the impermeability of the cell membranes of the tissue to gentamicin. Western blot analysis of MVs with S. flexneri Ipa-specific antibodies demonstrated that the invasion protein antigens IpaB, IpaC, and IpaD were present in MVs. Being bilayered, with outer faces composed of LPS and Ipa proteins, these MVs were readily engulfed by the otherwise impermeable membranes and eventually liberated their contents into the cytoplasmic substance of the host tissue.
我们研发了一种模型,用于测试庆大霉素等非膜渗透性治疗药物是否能够借助细菌膜泡递送至哺乳动物细胞内。许多革兰氏阴性菌在正常生长过程中会释放出膜泡(MVs),短暂暴露于庆大霉素下可增加这些膜泡的数量(J. L. 卡杜鲁加穆瓦和T. J. 贝弗里奇,《细菌学杂志》177:3998 - 4008,1995年),庆大霉素可被包裹在膜泡内。从福氏志贺菌中分离出庆大霉素诱导的膜泡(g - MVs),每微克膜泡蛋白中含有85±2纳克庆大霉素。用针对福氏志贺菌脂多糖(LPS)的特异性抗体对超薄切片进行免疫金电子显微镜标记,结果表明人亨勒407肠上皮细胞系可黏附并随后吞噬膜泡。将g - MVs与感染了福氏志贺菌的亨勒细胞进一步孵育后发现,g - MVs可穿透整个被感染细胞,并在孵育的第一个小时内使细胞内病原体数量减少约1.5个对数10 CFU。在宿主细胞的细胞质中检测到了抗生素,这表明g - MVs穿透后药物进入了细胞内。作为液体添加到组织培养生长培养基中的可溶性抗生素对细胞内细菌生长没有影响,这证实了该组织的细胞膜对庆大霉素具有不可渗透性。用福氏志贺菌Ipa特异性抗体对膜泡进行蛋白质印迹分析表明,侵袭蛋白抗原IpaB、IpaC和IpaD存在于膜泡中。这些膜泡具有双层结构,外表面由LPS和Ipa蛋白组成,很容易被原本不可渗透的细胞膜吞噬,并最终将其内容物释放到宿主组织的细胞质中。